This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good day. Thank you for standing by. Welcome to the SEER Inc. Third Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during this session, you'll need to press star 1 on your telephone. Please be advised today's conference may be recorded. If you require any further assistance, please press star, then zero. I would now like to hand the conference over to your host today, Carrie Mendeville, Investor Relations. Please go ahead.
spk00: Thank you. Earlier today, SEER released financial results for the quarter ended September 30th, 2021. If you have not received this news release, or if you'd like to be added to the company's distribution list, please send an email to investor at seer.bio. Joining me today from SEER are Omid Farraqsad, Chairman, CEO, and Founder, Omido Sadan, President and Chief Operating Officer, and David Horn, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release here issued today. For a more complete list and description, please see the risk factors section on the company's quarterly report on Form 10-Q for the quarter ended June 30th, 2021 and in its other filings with the Securities and Exchange Commission. Except as required by law, SEER disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast November 9th, 2021. With that, I'd like to turn the call over to Amin.
spk03: Thanks, Carrie. We're continuing to make outstanding progress and I could not be more pleased with the momentum as we approach the close of 2021 and prepare for broad commercial release in early 2022. Coming into 2021, we were focused on four key areas. First, setting the pace for innovation in the proteomics space. Second, leveraging the unique capabilities of our differentiated solutions. Third, coupling exceptional customer experience with transformative products, and fourth, forming strategic relationships with key customers and partners. And of course, as always, and most importantly, we're focused on continuing to grow our incredibly talented team. Now, 10 months into the year, we have demonstrated tangible progress across all four areas on innovation, our team has continued to push the boundaries of our technology at the interface of nanotechnology, biology, and machine learning to deepen our access to the proteome and its variants. On our unique capabilities, the power of this technology is its ability to enable highly robust, deep, unbiased proteomics at scale. As we progress through limited release, we're seeing an increasing number of customers planning at scale studies of a thousand samples or more. This is fundamentally transformative as prior to SEER, the most deep unbiased plasma proteomics studies that were done were in the size range of tens of samples. With regards to the customer experience, the ProteoGraph has been performing exceptionally well in the hands of customers. customers are extremely pleased with the entire spectrum of the experience, from efficiency of stall and validation, to training, to ease of use, and quality of data that they're generating. We're really excited to see several abstracts being presented in the fall conferences. And notably, these data were generated within just a few months following access to the prototype for most of these customers. On strategic relationships, We're making strong progress with our commercial partnerships to streamline workflows, expand geographic footprint, and set up global centers of excellence. We're also expanding our supply chain partnerships to enforce our ability to support our growing customer base globally. And of course, finally, with our team, we have continued to build our organization and add talent across a number of critical funds, including operations and quality, product development and data, and our commercial team. We are well positioned to scale our business as we head into 2022 and broad release. Now, we continue to see a strong market response to their prototype product suite. Revenue for the third quarter was $2.2 million, with $1.6 million of product-related revenue reflecting the increase in the install base and usage of the Protograph product suite. Our funnel of prospective customers continues to expand and include a broad range of global customer types, including pharma. We added new limited release customers in the third quarter, and we are on track to meet our goals of high single-digit number of sites across key applications and markets. We are particularly pleased with the caliber and ambitions of these customers. Early data was submitted by customers to the American Society for Mass Spectrometry, or ASMS, conference, which was last week, demonstrating how uniquely this technology enables deep unbiased plasma proteomics at scale. We saw customers apply our technology in new ways for the first time. including novel methods such as TMT, novel analysis such as glycoproteomics, and novel insights generated from deep and unbiased detection of disease-related proteins. Collectively, this body of data demonstrates the power and flexibility of our technology to empower customers and open up this market. Throughout our first two phases of commercialization, has been extremely pleased with how our technology has performed in customer hands, including ease with which the system has been implemented, robustness of how the assay performs, and quality of data that is being generated. We have also developed close customer relationships, which will enhance our ability to rapidly deploy applications, accelerate market creation, and drive adoption as we head into broad release. And the feedback we're receiving indicates that customers are really quite pleased, whether they come from the proteomics, genomics, or the background. They have been able to get up to speed and get going very quickly with our automated assay that requires little hands-on time to provide an easy-to-use, rapid, and reproducible workflow. it is clear that our solution is positioned to enable deep unbiased proteomics at scale for the first time. The ability for our technology to rapidly expand the discovery of new content at the amino acid or peptide level is one of the most significant variables in opening up this market. We're also uniquely solving the sampling problem, surveying the entire dynamic range of the plasma proteome. In doing so, will not only enable discovery of novel content at an unprecedented rate, but will also enrich the value that the entire proteomics ecosystem can create. This will benefit mass spec providers, software providers, and others, which is why so many of these companies have begun to partner with us. As we expand our footprint globally with what is already a disruptive product, we're also pushing a next set of innovations to further expand the capabilities of the ProteoGraph product suite. We're continuing to expand our software feature sets, streamline data management across our workflow, and leverage the power of our nanoparticles to lay a roadmap into the future. We are committed to driving a continuous stream of new products and product enhancements that will set the pace for innovation in proteomics. There continues to be a growing enthusiasm and energy around our technology. We continue to make strong progress across all dimensions of our business as our performance this quarter demonstrates. We're rapidly laying the groundwork for broad release in 2022. I'm inspired by the progress of our customers, proud of the strides we're making with our technology, and grateful for the hard work that the SEER team is putting in every day. With that, I will now turn the call over to Amit for more detail on our commercial progress.
spk06: Thank you. I'm excited by our strong commercial progress as we execute against our objectives for the year, and I believe that our measured approach to commercialization is paving the way for broad release customers to seamlessly adopt the paragraph product suite and scale their studies. We are already seeing increasing momentum at customer sites as they experience the power of our technology firsthand in their pilot studies, present on those studies, and reimagine what they can do in scalable future studies. We saw the first of these customer presentations at ASMS last week, starting with Oregon Health Sciences University Knight Cancer Institute, one of our collaboration sites. As we previously shared, following their pilot study, OHSU has obtained funding and is in the process of receiving samples to initiate a large-scale prostate cancer study that will include at least 500 and possibly up to 1,000 serum samples. This study would be the largest unbiased deep serum proteomics effort ever undertaken at the Institute and potentially ever anywhere. At ASMS, they shared a poster that documents results from a smaller pilot-scale study, These results and their very positive experience with the proteograph set the stage for their follow-on study, which will be highly scaled and carefully designed to a defined clinical endpoint. Their thoughtful and thorough plan for this scaled study will provide a blueprint that others can follow in tackling projects of similar size and complexity. Another collaboration customer, the Broad Institute, shared a poster using the proteograph to look at the plasma proteome of patients undergoing therapeutic ablation and monitoring the resultant tissue damage on a time course as a model for myocardial infarction. This data was compared with the Broad's previous method, which used extensive depletion and fractionation on similar samples, and was published in Nature Protocols in 2017. This poster demonstrated PERTIGRAPH's ability to dramatically reduce time and labor while robustly and deeply sampling the PERTIO with increased sensitivity. Researchers at Broad were able to detect an average of 2,200 proteins in each of three patient plasma samples across five time points, with a total of approximately 4,000 proteins identified across all measurements. The protograph enabled earlier detection of troponins, a key group of proteins whose abundance in plasma is an indicator of potential heart trauma, with many more peptides per sample, improving sensitivity versus their previous methods. They also detected new potential biomarkers using the PROTOGRAPH. These biomarkers need validation, but their detection points to the promise and power of the PROTOGRAPH to identify novel content and deepen biological insights. This study lays the foundation for future use of the PROTOGRAPH to study complex diseases at a scale of hundreds to thousands of samples while delivering the performance needed for translational and clinical research. Sanford Burnham Prevost Medical Discovery Institute. Researchers at Sanford Burnham demonstrated the compatibility of the Protograph product suite with tandem mass tag or TMT multiplexing, a popular method to increase the throughput and sensitivity of mass spectrometry. Using TMT, researchers processed four pooled samples in quadruplets and detected a total of 2,785 protein groups across those samples. with what we believe is unprecedented reproducibility for deep, unbiased proteomics shown by CVs of approximately 15%. Importantly, these proteins were detected across nine orders of magnitude of dynamic range and include important classes of proteins, such as 456 cancer-related proteins and at least 163 FDA-approved drug targets, 40 cytokines, and many TNF proteins that are in the picogram per milliliter quantities in plasma. This study demonstrates that the proteograph provides deep access across the plasma proteome, is highly adaptable to commonly used mass spec methods, and can be a highly valuable tool for clinical and translational research of varying scales. And finally, Protein Metrics, a privately held company whose software is employed industry-wide for protein characterization, including glycosylation analysis and a host of other post-translational modifications, or PTMs, use pilot data from the Proteograph product suite to look at the glycoproteome, which is quite important for biomarker discovery. Protein glycosylation is an important class of post-translational modifications that can have dramatic impact on protein structure and function in health and disease. Studying the proteome at the level of amino acid and peptide resolution and identifying novel glycoforms of proteins has important implications in biomarker discovery and drug target identification. In this study, the proteograph product suite enabled analysis of subpopulations of the glycoproteome without the need for subsequent glycopeptide-specific enrichment, demonstrating that the proteograph not only enables deep unbiased proteomics at scale, but can also identify a large range of proteoforms, including those found in post-translational modifications. These early results demonstrate the unique capabilities of the Proteograph product suite to unlock much of what is yet unknown about the proteome, its specific variants, and the critical role those protein variants play in governing biology. It is exciting and gratifying to see that once we put our technology into customers' hands, they are able to move quickly, observe important results, and generate novel insights even from initial pilot studies. Switching to our commercial progress, we are well on our way towards meeting our goal of high single-digit limited release customers, who, coupled with our collaboration customers, are forming an important base of Lighthouse accounts and providing blueprint for broad commercial release to follow. These customers represent an expanding set of customer types and application areas, including multibillion-dollar companies, some with substantial R&D and commercial operations across multiple geographies, including China. Heading into 2022, we have a growing pipeline of prospective customers across a diverse range of applications and markets, and we're ramping our commercial efforts to meet this demand. We are building out our commercial capabilities and operations. We are scaling our team, adding a number of highly talented individuals across marketing, sales, and support. And we're expanding our commercial partnerships to extend global reach and allow us to serve a diverse customer base. Overall, I'm extremely pleased with the execution of our commercial strategy over the first 10 months of the year. We are engaged with thought leaders and seeing large-scale projects planned or funded in record time. We are seeing robust performance of the product in customer hands, with compelling data being presented just months after customers gain access to the technology. We are building a broad and deep pipeline of prospects and are continuing to scale up our commercial organization to meet the opportunities. All of this makes me very confident as we round the corner into 2022 and towards broad release. With that, I will now turn the call over to David.
spk07: Thanks, Omid. Total revenue for the third quarter of 2021 was $2.2 million, compared to $72,000 in the third quarter of 2020. The increase in revenue was primarily due to sales of products related to our prototype product suite. Revenue consisted of sales of Proteograph SP-100 instruments, assay kits, platform evaluations, services, and grant revenue. Product-related revenue for the third quarter of 2021 was $1.6 million, including related party revenue of $787,000, and consisted of sales of SP-100 instruments, assay kits, and platform evaluations. Related party revenue of $787,000 represents product sales to Prognomic. As we expected and have described previously, Prognomic is ramping faster than other limited release customers, primarily due to their deep familiarity with the technology, which has allowed them to scale quickly as they interrogate hundreds and soon thousands of carefully collected and curated clinical samples. Service revenue was $500,000, and it represents the completion of a project under an agreement with a large pharmaceutical company. While we have no plans to enter into the service business as a normal course offering to our customers, We will continue to deploy our capabilities in unique, strategically important situations where, one, we want to catalyze adoption of our paragraph product suite to develop a specific market, or two, we partner with large institutions that have significant clinical assets to jointly undertake an important study. As such, you may see us recognize service revenue on an intermittent basis rather than consistently quarter to quarter. Grant revenue from our SBIR grant from the NIH was $10,000 in the third quarter of 2021, representing a decrease in activity related to this grant from the third quarter of 2020. Total gross profit inclusive of grant revenue was $1.2 million for the third quarter of 2021, representing a gross margin of 54%. Gross margin was driven by product mix and the recognition of service revenue in the quarter. Total operating expenses for the third quarter of 2021 were $19.6 million compared to $8.5 million in the third quarter of 2020. Research and development expenses for the third quarter of 2021 were $7.7 million compared to $4.8 million in the third quarter of 2020. The increase in R&D expenses was primarily driven by an increase in product development efforts related to our prototype product suite, including increased employee compensation costs and other related expenses, including stock-based compensation. due to growth in research and development personnel and increased costs related to the expansion of facilities and depreciation of laboratory equipment. Selling general and administrative expenses for the third quarter of 2021 were $11.9 million, compared to $3.7 million in the third quarter of 2020. The increase in SG&A expenses was primarily driven by an increase in employee compensation and other related expenses, including stock-based compensation, due to growth in selling general and administrative personnel. In addition, we incurred increased marketing costs related to the limited release phase of our commercialization plan and increased costs related to becoming a public company. Net loss for the third quarter was $18.4 million compared to $8.2 million in the third quarter of 2020. We ended the third quarter of 2021 with approximately $506.6 million in cash, cash equivalents, and investments. At this point, I would like to turn the call back to Omid for closing comments.
spk03: Thanks, David. I'm incredibly proud of our team at SEER and the progress we're making to transform proteomics and empower the scientific community. We continue to execute on our key objectives and look forward to updating you on our progress as we continue to open up a new gateway to the proteome. With that, we will now open it up to questions.
spk01: Thank you. If you have a question at this time, please press star, then 1 on your touch-tone telephone. If your question has been answered or you wish to remove yourself from the queue, please press the pound key. And our first question comes from the line of Derek D. Brown with Bank of America. Your line is open. Please go ahead.
spk04: Hello, and good afternoon. David, I know it's a little bit early, but any idea on the run rate pull-throughs on the instruments, and also just some color on what were instruments and consumables in terms of the product revenues?
spk08: Yeah, Derek, it is a little too early to talk about pull-through. I think, you know, again, given where we are in terms of folks getting the instrument and ramping up, it's really just too early. What I can tell you on product revenue and, you know, instrument versus consumable, I think the way to think about it this quarter is You know, this product revenue, as you'll see in the 10Q as we break it out, is primarily instrument revenue. And then related party revenue, which is prognomic revenue, is primarily consumable revenue. And this is exactly what we kind of expected to see at this point, given that prognomics roughly kind of two to three quarters ahead in terms of their familiarity with the technology, which has allowed them to get to the point of scale projects faster than others have simply because they've They've had a head start just given their familiarity here. But the instrumentation is the leading indicator of a growing install base we have and the customer breadth. And so we do expect to see, you know, that be a lead to expanding consumable revenue ramp as those customers get up to speed with, you know, with the technology and the projects they're working on.
spk04: Great. And the related party revenue was significant. quite a bit higher than what we thought it was going to be. Is that a good run rate for going forward? I'm just happy to understand the importance of it, but just would like to sort of get a better sense on just how to model it.
spk08: Yeah, I think the way to think about that, Derek, at least in the short term, is we expect prognomic, again, which is related party revenue, to be a similar percentage in terms of overall revenue. you know, quarter to quarter. I think you'll, as the other customer base broadens out and that revenue ramps, I think we'll start to see that decline a little bit as we move throughout 2022 and 2023. But in the short term, I think about it in kind of a similar zip code in terms of percent of revenue.
spk04: Got it. And just one question on some of the posters you presented. I noticed that on the Sanford Burnham poster, the CVs were about 15%. On the Broad, it was around 25% on the CVs. I'm just sort of curious. Can you help me understand the comparison between the labs of why one would have such a better reproducibility in one versus the other? As I said, I would just like to sort of understand what's the specific experiment and sort of doing with that. And I guess, are those 25% levels Is that a good range to sort of think about what your customers can use? Just trying to benchmark it towards other methods. Thanks.
spk03: Derek, I think as you look at CVs, you have to also think about the depth of the protein coverage that folks are seeing, the number of samples that they're looking at, So, for example, in the case of Broad, it was three samples over five time course, and then the protein sample across, sorry, the protein IDs across those samples approached 4,000. Individually, it was north of 2,000. So, that's a different kind of a readout that the, that the Vernon folks got. And again, it's just a function of the sample that they use. It's also a function of the detection and the gradient time that they use. So as you increase the depth, Derek, you would absolutely expect for that CV to widen. That is normal. So that's the way you should think of it.
spk04: Okay. Thanks. That helps. I'll get back to the queue. I don't want to hog all the questions. Thanks.
spk01: Thank you, and our next question comes from the line of Tejas Sabat with Morgan Stanley. Your line is open. Please go ahead.
spk05: Hi, this is Neil on for Tejas. Could you give us a quick update on Enlight Medical and progress of the proteograph in China, and any early color on what the order book looks like there?
spk03: Let me have Omid comment. on where we are with the China and the Enlightened experience. I think that may be more appropriate. If there is a need to kind of weigh in, I'll have David weigh in as well. Amit? Thank you.
spk06: So I think as we announced last quarter to you, we have signed a distribution deal with Enlight Medical. We're really excited about getting that relationship going. And so far, the progress we've made with them has been really quite positive and strong. As we mentioned to you, our original strategy was to get going to China in the middle of 2022. So we pulled that strategy, we pulled the execution of it up about a year. And so the way I would think about that one is that You know, we are just setting up as a distributor and we're doing it so that we can actually begin to expand on our book of business in China. And so I think you can expect to see results of that play out over the course of time, but primarily in 2022. But I'm really quite pleased with the way that the relationship is already gotten off the ground, the level of engagement by Enlight and the infrastructure and process we're putting in place to have a very successful business in China moving forward.
spk05: Great, thank you. And how do you think about the Salesforce ramp ahead of broader commercial launch in light of tighter labor market conditions right now?
spk03: Look, we're not disclosing the number of reps. Suffice it to say that we've substantially grown our commercial team in 2021, expect to do it in 2022. I have to say that we've probably attracted some of the best commercial minds at the senior level in this company, and these are folks that have really decades of experience selling life science tools and the commercial model that they use, including, by the way, the way they staff their team, I expect we're going to be able to meet customer demand in a very efficient way. I think, Omid, your comment, but in general, even since day one where we started, we're always hiring about one to two quarter ahead so that Folks are up and running and up to speed by the time the quarter comes that we need them to execute. I think that's been the plan. I'm very proud of the commercial team that we've built. Vinitibh, Omid wants to add to that.
spk06: Maybe just a couple of things. So totally acknowledging a tighter labor market, but I think to the point that Omid raised, given the range and caliber of people we have around the table and the commercial team already, the opportunity that the company represents, We haven't really had any complexity or difficulty either identifying, recruiting, or bringing on board commercial staff, be it in sales, support, or marketing. So I feel really good about where we are in terms of today, quite frankly, and our preparation for 2022.
spk05: Got it. That's it for me. Thank you for taking my question.
spk01: Thank you. And if you have a question at this time, please press star then 1. And our next question comes from the line of Tycho Peterson with JP Morgan. Your line is open. Please go ahead.
spk02: Hi, this is Rachel Owen for Tycho. Thanks for taking the questions. So first off, could you just talk about if you faced any supply chain or inflationary pressures this quarter? And then supply chain constraints have obviously gotten tighter in recent weeks, and we've been hearing about it more. So could you talk about your confidence around ramping inventory ahead of the broader rollout in 22?
spk03: I'm sorry, the last question, can you repeat your last question for me?
spk02: Yep, just your confidence with the broader rollout in 2022, given the recent supply chain constraints that we've been hearing about across the industry.
spk03: Got it. Okay. So look, to date, our supply chain hasn't been affected by COVID. As we had anticipated, a lot of these potential shortages early and work with our suppliers to ensure timely delivery of the components that we need to support our customer base. So based on what we know today, that's all I can speak about. And also of the very close relationship that we have with our suppliers, we don't anticipate any supply chain shortage. But of course, COVID itself is unprecedentedly fluid. So it's hard for me to anticipate what may be coming around the corner. But suffice it to say the visibility that we have is we're on the improving side of that curve. And we don't really anticipate any difficulty. Now, the one challenge I would say we have is with XUS where we are actually seeing some difficulty just getting there in person just because of challenges that just international travel brings to our team in order to get there and then do install and really have a good customer experience. But again, we're managing those things. So in U.S., feel very good about where we are in terms of both the balance of 2021 and heading into broad release in 2022. And then as far as ex-U.S., I think we'll have to see how that plays out. But certainly, it does create some complexity for us. Omi, do you want to add to that?
spk02: Great, that's helpful.
spk03: I think you got it.
spk02: Perfect. Okay, and then last one from me. So I appreciate the commentary around that $500,000 of service revenue. Can you just give us some more color on that project with the large pharma company? How did that service product come to fruition? And then it sounds like that product is complete, so can you talk about any feedback that you received from that large pharma partner?
spk03: Yeah, let me, so first of all, we're not talking much about the specifics of these projects, but let me see if Omid feels comfortable giving as much color as we can.
spk06: Sure. I think, yeah, so the specifics of this project is, you know, again, this is a project customer, because they are a customer, they actually do a service project, is really interested in getting going with a reasonable-sized project pretty quickly and getting results back in a relatively fast turnaround time. And as we've told you, we anticipated this, which is why we're looking to actually set up and stand up these centers of excellence. And now we have potential candidates at centers of excellence among our actually existing early access, so rather limited release customers. But it is going to take us a little bit of time to get them all completely set up to the point that they can process these numbers of samples. And so this was really a temporal issue where the customer wanted to have data very quickly on a large sample study, and we felt very comfortable that we could execute against that, which is what we did. And as David mentioned, from time to time, there are going to be these types of projects where for strategic reasons, from a timing reason, for perhaps confidentiality reasons on the part of the customer, we end up being the best executor of those types of projects for those customers. We'll be opportunistic in those instances because our primary business is not a services model. That is what we want other people to do, but from time to time, circumstances are going to put us in a position to be the best, if you will, site to carry on a project. But the way I think about these things are, you know, these are largely oftentimes forerunners of future demand for similar type or larger scale projects.
spk02: That's great.
spk01: Thank you. Thank you. And I'm showing no further questions. And this does conclude today's question and answer session. Ladies and gentlemen, this also does conclude today's conference call. Thank you for participating. You may now disconnect. Everybody have a great day.
Disclaimer